Ginkgo Bioworks
American biotechnology company / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Ginkgo Bioworks?
Summarize this article for a 10 year old
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT,[3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology.[4][5][6][7] The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies,[8] valued at $4.2 billion in 2019.[9] It raised $290 million in September and $350 million in October of that year.[8] Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.[10]
Company type | Public company |
---|---|
| |
Industry | Biotechnology |
Founded | 2008; 16 years ago (2008) in Boston, Massachusetts, U.S. |
Founders | Tom Knight, Jason Kelly, Reshma Shetty, Barry Canton, Austin Che[1] |
Headquarters | , U.S. |
Key people | Shyam Sankar (Chair Board of Directors), Jason Kelly (CEO) |
Revenue | US$478 million (2022) |
US$−2.2 billion (2022) | |
US$−2.1 billion (2022) | |
Total assets | US$2.54 billion (2022) |
Total equity | US$1.74 billion (2022) |
Number of employees | 1,292 (December 2022) |
Website | ginkgobioworks |
Footnotes / references [2] |